Merck & Company -Evaluating a Drug Licensing Opportunity(영문)
- 등록일 / 수정일
- 페이지 / 형식
- 자료평가
- 구매가격
- 2009.02.13 / 2019.12.24
- 7페이지 / doc (MS워드 2003이하)
- 평가한 분이 없습니다. (구매금액의 3%지급)
- 1,400원
최대 20페이지까지 미리보기 서비스를 제공합니다.
자료평가하면 구매금액의 3%지급!
1
2
3
4
5
6
7
추천 연관자료
- 목차
-
INTRODUCTION
Merck & Company : Evaluating the Licensing Opportunity
Brief introduction of Merck and its agenda regarding Davanrik project
1. Expectaion of costs and chances of success for each phase
2. Cost of launches and Potential profits
3. Decision Tree & Calculation
CONCLUSION
- 본문내용
-
Merck & Company : Evaluating the Licensing Opportunity
Various recently-born biotech companies sell their technologies in either finished or early stage to bigger companies in need of financing capital to preceed business, while those bigger companies acquire technologies to scout for promising profitable business. This sort of process needs numbers of decision makings and agreements from both parties on the valuation methods is crucial here. The valuation method being used has to hold objective validity and generality.
For the managers to make accurate forecast of future profitability in managing companies, quantified decision making process is needed. Here we are dealing about whether Merck should give financial support to the R&D project of Davanrik offered by LAB, and about the process of valuation and the final decision. First we are to make brief of LAB’s business proposal and practice detailed valuation functions to decide if the proposal is profitable or not. And finally we will make a decision based on the valuation process in perspective of Rich Kender, Vice President of Financial Evaluation & Analysis of Merck.
Brief introduction of Merck and its agenda regarding Davanrik project
As a world-class pharmaceutical company concentrated on R&Ds, Merck is performing various researches and developments upon medical supplies for human and animals. Merck is providing Pharmaceutical Benefit Management (i.e. PBM) through a company called Merck-Medco Managed Care. Apparently it is a giant pharmaceutical company with more than 15 blockbuster medical supplies, revenue of $3270 million and net profit of $590 million, ever since 1995. One constraint of Merck is that most of its profit is over-concentrated on the major top 4 items, and in order to diversification of profits Merck is facing a pressure to launch a new business item or take another complementary strategy through biotech and internal R&D.
LAB Pharmaceuticals has already finished developing Davanrik, an antidepressant. Even though it carries substantial medical/economical feasibility for being effective on both hypochondria and obesity, LAB cannot afford the capital to proceed clinical demonstrations ahead the actual sale to acquire licensing. This is the reason why LAB offered Merck of technical affiliation.
At the following step, we are to evaluate the profitability of Davanrik based on the expected length of time and expense, chances of success that LAB has suggested.
자료평가
-
아직 평가한 내용이 없습니다.
오늘 본 자료
더보기
최근 판매 자료
- 도미노피자의 SCM분석
- 이미지에 따른 패션 코디네이션의 종류
- 상쾌환PPT(숙취해소제 환 제품군 TOPof MIND 제고를 위한 IMC전략)
- 동기부여 개념과 이론분석및 동기부여 기업사례연구(삼성전자,구글,스타벅스,사우스웨스트,미라이공업)및 기업내 동기부여에 대한 나의의견
- 핫식스 제품분석과 SWOT분석및 핫식스 현재 마케팅전략분석및 핫식스 향후 국내외 마케팅전략 제안 PPT
- 오뚜기 기업분석과 제품분석및 swot 분석, 마케팅 전략,브랜드 이미지 ppt
- [물류경영] 바릴라스파 `Barilla SpA` 문제점 및 해결방안
- 사우스웨스트 항공 원가우위, 차별화 전략
- [재무제표 분석] 홈쇼핑 산업분석 -GS홈쇼핑과 CJ홈쇼핑의 가치평가를 중심으로
- 이마트 E-마트의 공급사슬관리 SCM
저작권 관련 사항 정보 및 게시물 내용의 진실성에 대하여 레포트샵은 보증하지 아니하며, 해당 정보 및 게시물의 저작권과 기타 법적 책임은 자료 등록자에게 있습니다. 위 정보 및 게시물 내용의 불법적 이용, 무단 전재·배포는 금지됩니다. 저작권침해, 명예훼손 등 분쟁요소 발견시 고객센터에 신고해 주시기 바랍니다.